ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

NCT04639024 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped ADCT is reallocating all resources to the phase III program.

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Neoplasm (MDS/MPN)

Interventions

DRUG: ADCT-301

Sponsor

Gwynn Long, M.D.

Collaborators

[object Object]